All In Biotech

Drug Trial Radar · NCT07915791

A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

ALARMONY: A Phase 2 Randomized, Double Blind, Placebo Controlled Multi-center Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe COPD

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 279 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

279

Planned (sponsor's estimate)

Start

Oct 29, 2026

Primary completion

Mar 7, 2029

Study completion Feb 6, 2030

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is for adult participants with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) who continue to experience exacerbations despite standard of care triple therapy treatment. It will assess the effectiveness and safety of two investigational drugs, GSK3862995B and GSK5784283, given together compared to a placebo in addition to standard of care.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • GSK3862995BDrug

    Participants will receive GSK3862995B.

  • GSK5784283Drug

    Participants will receive GSK5784283.

  • PlaceboDrug

    Participants will receive matching Placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Moderate/severe Exacerbations in Former SmokersTime frame: Up to 72 weeks

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Newport Beach, California · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Derby, Kansas · Recruiting

  • GSK Investigational Site

    Columbia, Maryland · Recruiting

  • GSK Investigational Site

    Oklahoma City, Oklahoma · Recruiting

  • GSK Investigational Site

    Philadelphia, Pennsylvania · Recruiting

  • GSK Investigational Site

    Rock Hill, South Carolina · Recruiting

  • GSK Investigational Site

    Tomball, Texas · Recruiting

  • GSK Investigational Site

    Bradford, United Kingdom · Recruiting

  • GSK Investigational Site

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.